Long-term persistence of NMDAR antibodies after encephalitis with de novo occurrence of demyelinating disorder.


Journal

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 01 06 2020
accepted: 15 09 2020
pubmed: 30 9 2020
medline: 15 5 2021
entrez: 29 9 2020
Statut: ppublish

Résumé

The issue of persistence of NMDAR antibodies after encephalitis is not fully elucidated and their relationship with demyelinating disorders has been suggested. A female patient showed at the age of 18 an acute neurological disorder (with psychiatric symptoms, focal seizures, orofacial dyskinesias and hypoventilation requiring ventilatory support) clinically mimicking anti-NMDAR encephalitis. At that time specific laboratory tests were not available, CSF revealed oligoclonal bands and MRI was negative. The patient had full recovery after first line immunotherapy (i.v. steroids and immunoglobulins). Fifteen years later, at the age of 33, she was hospitalized with subacute right hemiparesis and MRI disclosed multiple T2 hyperintensities in the white matter, one of them in the left midbrain showing contrast enhancement. Serum and CSF NMDAR antibodies were positive while MOG and AQP4 antibodies were negative. Intravenous methylprednisolone led to complete recovery. This case report provides evidence of a long-term persistence of NMDAR antibodies even 15 years after the encephalitis and raises the suspicion of a possible causal relationship between NMDAR antibodies and demyelinating disorders in the form of multiple sclerosis.

Identifiants

pubmed: 32989588
doi: 10.1007/s10072-020-04729-3
pii: 10.1007/s10072-020-04729-3
doi:

Substances chimiques

Autoantibodies 0
Receptors, N-Methyl-D-Aspartate 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

301-303

Références

Dalmau J, Armanguè T, Planagumà J et al (2019) An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol 18:1045–1057
doi: 10.1016/S1474-4422(19)30244-3
Titulaer MJ, Hoftberger R, Iizuka T et al (2014) Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis [J]. Ann Neurol 75(3):411–428
doi: 10.1002/ana.24117
Baheerathan A, Brownlee WJ, Chard DT, Shields K, Gregory R, Trip SA (2017) Antecedent anti-NMDA receptor encephalitis in two patients with multiple sclerosis. Mult Scler Relat Disord. 12:20–22. https://doi.org/10.1016/j.msard.2016.12.009
doi: 10.1016/j.msard.2016.12.009 pubmed: 28283100
Lekoubou A, Viaccoz A, Didelot A, Anastasi A, Marignier R, Ducray F, Rogemond V, Honnorat J (2012) Anti-N-methyl-D-aspartate receptor encephalitis with acute disseminated encephalomyelitis-like MRI features. Eur J Neurol 19(2):e16–e17
doi: 10.1111/j.1468-1331.2011.03617.x
Ran Y, Wang L, Zhang F, Ao R, Dong Z, Yu S (2017) Anti-NMDAR encephalitis followed by seropositive neuromyelitis optica spectrum disorder: a case report and literature review. Clin Neurol Neurosurg 155:75–82. https://doi.org/10.1016/j.clineuro.2017.02.016
doi: 10.1016/j.clineuro.2017.02.016 pubmed: 28282627
Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, Suzuki K, Lynch DR, Suzuki N, Hata T, Dalmau J (2008) Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 70:504–511
doi: 10.1212/01.wnl.0000278388.90370.c3
Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, Mccracken L, Leypoldt F et al (2014) Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 13:167–177
doi: 10.1016/S1474-4422(13)70282-5
Hansen HC, Klingbeil C, Dalmau J, Li W, Weissbrich B, Wandinger KP (2013) Persistent intrathecal antibody synthesis 15 years after recovering from anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurol 70:117–119
doi: 10.1001/jamaneurol.2013.585
Waschbisch A, Kallmunzer B, Schwab S et al (2014) Demyelinating disease and anti-NMDAR IgG antibodies: a case report. Ann Neurol 75:411–428
doi: 10.1002/ana.24117
Uzawa A, Mori M, Takahashi Y, Ogawa Y, Uchiyama T, Kuwabara S (2012) Anti-N-methyl D-aspartate-type glutamate receptor antibody-positive limbic encephalitis in a patient with multiple sclerosis. Clin Neurol Neurosurg 114:402–404
doi: 10.1016/j.clineuro.2011.10.047

Auteurs

Maria Tappatà (M)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Unit of Neurology, Bellaria Hospital, Bologna, Italy. maria.tappata@ausl.bo.it.

Patrizia Riguzzi (P)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Unit of Neurology, Bellaria Hospital, Bologna, Italy.

Lilia Volpi (L)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Unit of Neurology, Bellaria Hospital, Bologna, Italy.

Luca Albini Riccioli (L)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Unit of Neuroradiology, Bellaria Hospital, Bologna, Italy.

Roberta Pantieri (R)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Unit of Neurology, Bellaria Hospital, Bologna, Italy.

Roberto Michelucci (R)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Unit of Neurology, Bellaria Hospital, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH